The French trial called STIM (Stop Imatinib) - Chronic Myeloid Leukemia
Important notice: You must inform your CML doctor or a qualified doctor if you want to stop your medication. The material presented here is for information purposes only; it is not a substitute for your physician’s guidance and care.... See our disclamer
FORUMS
How are trial participants doing who got off Gleevec? from NewCmlDrg.com
"Patients with CML who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR" from LLS
Can Therapy With TKIs for CML Ever Be Stopped? from LLS
Tasigna "Discontinuation Study" from LLS
How are trial participants doing who got off Gleevec? from NewCmlDrg.com
"Patients with CML who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR" from LLS
Can Therapy With TKIs for CML Ever Be Stopped? from LLS
Tasigna "Discontinuation Study" from LLS
ARTICLES
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease:
results from the TWISTER Study
May 23, 2013, PublMed
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib
discontinuation in patients with CML
May 9, 2013, PublMed
Can Therapy With TKIs for CML Ever Be Stopped?
March 21, 2013, OncLive
Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib
February 26, 2013, PublMed
Is Stopping CML Treatment a Viable Option Now? VIDEO
January 17, 2013, Patient Power
Can we safely stop TKI therapies? Experience from the STOP trials VIDEO
Delphine Rea, Hôpital Saint-Louis, Paris, France
December 2012, iCMLf
Patient Preferences for Stopping Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
December 10, 2012, ASH 2012
Activation Levels of Natural Killer Cells and CD8+ T Cells Correlate Highly with Sustained Complete Molecular Response After Discontinuation of Imatinib in Chronic Myeloid Leukemia Patients
December 10, 2012, ASH 2012
Early Molecular Response and Female Sex Strongly Predict Achievement of Stable Undetectable BCR-ABL1, a Criterion for
Imatinib Discontinuation in Patients with CML
December 9, 2012, ASH 2012
Is going for cure in chronic myeloid leukemia possible and justifiable?
December 8, 2012, Hematology
Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia
November 21, 2012, Journal Blood
New Data Confirm Safety of Stopping Imatinib in Leukemia
July 4, 2012, Help with cancer.org
Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia
June 2012, Haematologica
Biomarker Assay for Residual Chronic Myeloid Leukemia Stem/Progenitor Cells during Treatment with ABL-Tyrosine Kinase Inhibitors (PDF)
May 12, 2012, Molecular Biomarkers & Diagnosis
CML: Stopping TKI Therapy May Be Possible for Some Patients
March 10, 2012, Oncology Times
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease:
results from the TWISTER Study
May 23, 2013, PublMed
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib
discontinuation in patients with CML
May 9, 2013, PublMed
Can Therapy With TKIs for CML Ever Be Stopped?
March 21, 2013, OncLive
Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib
February 26, 2013, PublMed
Is Stopping CML Treatment a Viable Option Now? VIDEO
January 17, 2013, Patient Power
Can we safely stop TKI therapies? Experience from the STOP trials VIDEO
Delphine Rea, Hôpital Saint-Louis, Paris, France
December 2012, iCMLf
Patient Preferences for Stopping Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
December 10, 2012, ASH 2012
Activation Levels of Natural Killer Cells and CD8+ T Cells Correlate Highly with Sustained Complete Molecular Response After Discontinuation of Imatinib in Chronic Myeloid Leukemia Patients
December 10, 2012, ASH 2012
Early Molecular Response and Female Sex Strongly Predict Achievement of Stable Undetectable BCR-ABL1, a Criterion for
Imatinib Discontinuation in Patients with CML
December 9, 2012, ASH 2012
Is going for cure in chronic myeloid leukemia possible and justifiable?
December 8, 2012, Hematology
Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia
November 21, 2012, Journal Blood
New Data Confirm Safety of Stopping Imatinib in Leukemia
July 4, 2012, Help with cancer.org
Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia
June 2012, Haematologica
Biomarker Assay for Residual Chronic Myeloid Leukemia Stem/Progenitor Cells during Treatment with ABL-Tyrosine Kinase Inhibitors (PDF)
May 12, 2012, Molecular Biomarkers & Diagnosis
CML: Stopping TKI Therapy May Be Possible for Some Patients
March 10, 2012, Oncology Times
Minimal Residual Disease and Discontinuation of Therapy in Chronic Myeloid Leukemia: Can We Aim at a Cure?
December 10, 2011, Hematalogy
Recent advances in the path toward the cure for chronic myeloid leukemia
September 30, 2011, NCBI
Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features
August 2, 2011, Haematologica
Stopping Dasatinib and Nilotinib Explored in Chronic Myeloid Leukemia
July 6, 2011, Oncology Practice
Stopping CML therapies and eradicating CML: Patient perspective from EHA
June 15, 2011, CML Advocates Network
Multicenter Trial Estimating the Persistence of Molecular
Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib (STIM 2)
April 2011, ClinicalTrials.gov
Discontinuation of imatinib may be possible in chronic myelogenous leukemia
March 3, 2011, Cancer Journal for Clinicians
December 10, 2011, Hematalogy
Recent advances in the path toward the cure for chronic myeloid leukemia
September 30, 2011, NCBI
Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features
August 2, 2011, Haematologica
Stopping Dasatinib and Nilotinib Explored in Chronic Myeloid Leukemia
July 6, 2011, Oncology Practice
Stopping CML therapies and eradicating CML: Patient perspective from EHA
June 15, 2011, CML Advocates Network
Multicenter Trial Estimating the Persistence of Molecular
Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib (STIM 2)
April 2011, ClinicalTrials.gov
Discontinuation of imatinib may be possible in chronic myelogenous leukemia
March 3, 2011, Cancer Journal for Clinicians
CML Patients Stay in Remission Two Years After Imatinib
October 21, 2010, DoctorsLounge
Some with leukemia can safely stop Gleevec
October 2010, Caring4cancer
Could Some Patients Stop Taking Their CML Pills? VIDEO
October 2010, Patient Power
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
October 2010,The Lancet Oncology, Early Online Publication
Some With Once-Deadly Leukemia Can Take a Break From Gleevec
Small minority of CML patients went off the drug for 2 years with no sign of recurrence
October 2010, Healthday, U.S. News
STIM Study Examines Sustainability of Complete Molecular Response After Stopping Imatinib in CML
January 2010, MedConnect
Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells
December 8, 2009, Heamatologica
STIM Study Shows CML Complete Molecular Remission
Possible to Maintain Following Imatinib Discontinuation
December 19, 2008, CMLSupport
The Majority of Chronic Myeloid Leukaemia Patients Who Cease Imatinib after Achieving a Sustained Complete Molecular Response (CMR) Remain in CMR, and Any Relapses Occur Early
December 6, 2008, CMLinfo
October 21, 2010, DoctorsLounge
Some with leukemia can safely stop Gleevec
October 2010, Caring4cancer
Could Some Patients Stop Taking Their CML Pills? VIDEO
October 2010, Patient Power
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
October 2010,The Lancet Oncology, Early Online Publication
Some With Once-Deadly Leukemia Can Take a Break From Gleevec
Small minority of CML patients went off the drug for 2 years with no sign of recurrence
October 2010, Healthday, U.S. News
STIM Study Examines Sustainability of Complete Molecular Response After Stopping Imatinib in CML
January 2010, MedConnect
Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells
December 8, 2009, Heamatologica
STIM Study Shows CML Complete Molecular Remission
Possible to Maintain Following Imatinib Discontinuation
December 19, 2008, CMLSupport
The Majority of Chronic Myeloid Leukaemia Patients Who Cease Imatinib after Achieving a Sustained Complete Molecular Response (CMR) Remain in CMR, and Any Relapses Occur Early
December 6, 2008, CMLinfo
